LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting therapies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
Materials in this section
TAGline: Delivering on the Promise of Long-Acting Formulations
October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria. More
Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C
The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More
Illustrated Glossary for LATs
The Glossary compiles frequent terms and concepts used in the research and development of long-acting technologies. More
